TC Biopharm (Holdings) Plc (TCBP)
| Previous Close | 1.4700 |
| Open | 1.5200 |
| Bid | 1.3800 x 200 |
| Ask | 1.6800 x 200 |
| Day's Range | 1.5200 - 1.5764 |
| 52 Week Range | 0.8500 - 268.0000 |
| Volume | |
| Avg. Volume | 4,720,074 |
| Market Cap | 5.037M |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -23.7100 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 140.00 |
PR NewswireTCBP Announces Execution of Non-Binding Letter of Intent for Acquisition of NK Platform Technologies
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent as part of its M&A strategy aimed at expanding its therapeutic platform and leveraging NK (natural killer) cells in treating both solid tumors and other indications.
- PR Newswire
TCBP Increasing Treatment Capacity with Expanded Manufacturing Process
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it is developing a streamlined and scaled-up manufacturing process which will increase its treatments capacity from 52 patient treatments per year to more than 1,000.
- PR Newswire
TCBP Adjourns General Meeting Until a Later Date
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has adjourned its General Meeting of the Company to a later date.
